Valuation : ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 58.41B 379M 326M 308M 280M 524M 36.26B 529M 3.66B 1.41B 18.39B 1.42B 1.39B P/E 2027 *
12.5x
P/E 2028 * 10.6x
Enterprise Value 58.41B 379M 326M 308M 280M 524M 36.26B 529M 3.66B 1.41B 18.39B 1.42B 1.39B EV / Sales 2027 *
0.8x
EV / Sales 2028 * 0.78x
Free-Float
63.84%
Yield 2027 *
3.16%
Yield 2028 * 3.4%
09-04 Metagen Therapeutics, Inc. announced that it has received ¥3.71 billion in funding from a group of investors CI
08-04 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-25 Declaration of Voting Results by Asuka Pharmaceutical CI
05-27 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
05-25 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
05-11 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
04-14 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
03-24 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
1 day-0.19%
1 week-0.77%
Current month-2.74%
1 month+2.34%
3 months-19.02%
6 months-8.58%
Current year+0.93%
1 week 2,036
Extreme 2036
2,096
1 month 2,026
Extreme 2026
2,238
Current year 1,917
Extreme 1917
3,045
1 year 1,917
Extreme 1917
3,045
3 years 1,584
Extreme 1584
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 24/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 24/06/2025
Director/Board Member 67 01/04/2021
Director/Board Member 42 01/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-0.77%-15.87%+23.40% 381M
-0.11%-3.16%+48.82%+88.56% 1,002B
-0.27%-4.34%+51.52%+63.75% 644B
+1.63%-2.00%+20.49%+71.10% 443B
-0.63%-1.06%+28.11%+34.59% 343B
+0.43%-14.61%+9.88%+27.26% 262B
+0.93%-1.82%-1.82%+8.41% 245B
-2.25%-13.88%+37.33%+46.14% 212B
-0.90%-5.09%-15.47%-57.75% 199B
-0.58%-4.24%+25.65%+87.97% 181B
Average -0.02%-4.56%+18.86%+39.34% 353.01B
Weighted average by Cap. +0.27%-4.24%+31.84%+55.68%

Financials

2027 *2028 *
Net sales 73.12B 475M 408M 385M 351M 656M 45.39B 662M 4.59B 1.77B 23.02B 1.78B 1.74B 74.96B 487M 418M 395M 360M 672M 46.53B 679M 4.7B 1.81B 23.6B 1.83B 1.79B
Net income 4.67B 30.31M 26.07M 24.6M 22.41M 41.89M 2.9B 42.27M 293M 113M 1.47B 114M 111M 5.52B 35.86M 30.84M 29.1M 26.51M 49.56M 3.43B 50.01M 347M 133M 1.74B 135M 132M
Net Debt - -
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,611
Date Price Change Volume
10/09/26 ¥2,057.00 -0.19% 37,700
09/09/26 ¥2,061.00 -1.39% 49,600
08/09/26 ¥2,090.00 +0.38% 46,400
07/09/26 ¥2,082.00 +1.61% 65,100
04/09/26 ¥2,049.00 -1.06% 52,100
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,057.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+16.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4886 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!